Incidence and Prevalence of Inflammatory
Bowel Disease 9
This is "a clear-cut scenario where one of the inflammatory
agents blocks insulin action," says Paresh Dandona of the University of Buffalo School of Medicine.
We believe that a test to detect and measure levels of HMGB1 in the bloodstream could play an important role in diagnosing acute diseases resulting in multi-organ failure, including sepsis and septic shock, as well as chronic inflammatory
diseases, such as rheumatoid arthritis.
Crohn's disease is a form of inflammatory
bowel disease that features intestinal symptoms such as nonbloody diarrhea, abdominal pain, fatigue, fever, and weight loss.
In preclinical studies, Isis and its collaborators have demonstrated substantial efficacy of a mouse equivalent of ISIS 2302 in the prevention of organ transplant rejection and collagen-induced arthritis in the prevention and treatment of dextran sulfate-induced inflammatory
bowel disease and in the reduction of inflammatory
response in a variety of other models of inflammation.
Initially, this involves screening for the presence of the receptor on normal and diseases human tissues across a range of autoimmmune and chronic inflammatory
These findings identify CR1 "as a potential agent for the suppression of complement-dependent tissue injury in auto-immune and inflammatory
diseases," the researchers say.
Crohn's Disease is a life-long, chronic inflammatory
disease of the intestines, often leading to abdominal pain, disability, and surgical removal of the affected portion of the bowel in more than half of patients with the disease.
Empey, who has investigated other 5-LO inhibitors at the University of Alberta in Edmonton, says that to date no one has shown that blocking leukotrienes will prevent or heal inflammatory
Even if administered 2, 4, or 6 hours after a lethal dose of endotoxin -- well after the inflammatory
cascade was initiated -- significant protection was observed (60 percent, 50 percent, 30 percent survival respectively vs.
is presenting clinical and preclinical data from studies of the company's drug candidate Traficet-EN[R] (CCX282-B) a first-in-class, orally active, anti-inflammatory
agent that targets the chemokine receptor known as CCR9, at the 2006 Crohn's and Colitis Foundation of America's (CCFA) National Research and Clinical Conference/Fifth Annual Advances in the Inflammatory
Bowel Diseases meeting being held December 1-3, 2006 in Miami, FL.
These studies show that ARAs inhibit specific cell adhesion molecules and the accumulation of neutrophils (certain white blood cells), both of which contribute to the inflammatory